Hydrochlorothiazide and bendroflumethiazide in low doses--a comparative trial.
The effect and tolerability of hydrochlorothiazide 12.5 mg and bendroflumethiazide 2.5 mg were compared in 36 previously untreated hypertensives in a double-blind randomized multicenter trial. The results show a significant blood pressure reduction with both hydrochlorothiazide 12.5 mg and bendroflumethiazide 2.5 mg both at month 6 and 12 compared with month 0. Serum potassium was not significantly changed after twelve months of therapy with either of the thiazide compared with month 0. There was no significant difference between hydrochlorothiazide and bendroflumethiazide with respect to the hypotensive effect, the effect on potassium and uric acid in serum, fasting blood glucose, or any other variable studied. Few subjective side effects were reported.
D000328:Adult; D000368:Aged; D001539:Bendroflumethiazide / Q000627:therapeutic use*; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use*; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011188:Potassium / Q000097:blood; D011897:Random Allocation; D014527:Uric Acid / Q000097:blood
D001786:Blood Glucose; D006852:Hydrochlorothiazide; D014527:Uric Acid; D001539:Bendroflumethiazide; D011188:Potassium